107 related articles for article (PubMed ID: 9037248)
1. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones.
de Isabella P; Palumbo M; Sissi C; Carenini N; Capranico G; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC; Zunino F
Biochem Pharmacol; 1997 Jan; 53(2):161-9. PubMed ID: 9037248
[TBL] [Abstract][Full Text] [Related]
2. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity.
Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M
J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
[TBL] [Abstract][Full Text] [Related]
4. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M
Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029
[TBL] [Abstract][Full Text] [Related]
5. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells.
Hazlehurst LA; Krapcho AP; Hacker MP
Biochem Pharmacol; 1995 Sep; 50(7):1087-94. PubMed ID: 7575665
[TBL] [Abstract][Full Text] [Related]
6. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains.
Sissi C; Moro S; Zagotto G; Ellis M; Krapcho AP; Menta E; Palumbo M
Anticancer Drug Des; 1999 Jun; 14(3):265-74. PubMed ID: 10500501
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
Leteurtre F; Kohlhagen G; Paull KD; Pommier Y
J Natl Cancer Inst; 1994 Aug; 86(16):1239-44. PubMed ID: 8040892
[TBL] [Abstract][Full Text] [Related]
8. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
9. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
[TBL] [Abstract][Full Text] [Related]
10. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones.
Hazlehurst LA; Krapcho AP; Hacker MP
Cancer Lett; 1995 May; 91(1):115-24. PubMed ID: 7750086
[TBL] [Abstract][Full Text] [Related]
11. Bis-substituted hydroxy-anthracenediones: DNA binding and biological activity.
Palumbo M; Palù G; Gia O; Ferrazzi E; Gastaldi S; Antonello C; Meloni GA
Anticancer Drug Des; 1987 Apr; 1(4):337-46. PubMed ID: 3450303
[TBL] [Abstract][Full Text] [Related]
12. Aza-bioisosteres of 9, 10-anthracenedione: a modulation of DNA sequence specificity.
Sissi C; Capranico G; Menta E; Palumbo M
Mol Pharmacol; 1996 Oct; 50(4):838-45. PubMed ID: 8863828
[TBL] [Abstract][Full Text] [Related]
13. Novel ametantrone-amsacrine related hybrids as topoisomerase IIβ poisons and cytotoxic agents.
Zagotto G; Gianoncelli A; Sissi C; Marzano C; Gandin V; Pasquale R; Capranico G; Ribaudo G; Palumbo M
Arch Pharm (Weinheim); 2014 Oct; 347(10):728-37. PubMed ID: 25042690
[TBL] [Abstract][Full Text] [Related]
14. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin.
Fisher GR; Patterson LH
Cancer Chemother Pharmacol; 1992; 30(6):451-8. PubMed ID: 1394801
[TBL] [Abstract][Full Text] [Related]
15. Characterization of anthracenediones and their photoaffinity analogs.
Chou KM; Krapcho AP; Horn D; Hacker M
Biochem Pharmacol; 2002 Mar; 63(6):1143-7. PubMed ID: 11931847
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, DNA binding, topoisomerase II inhibition and cytotoxicity of two guanidine-containing anthracene-9,10-diones.
Routier S; Bernier JL; Catteau JP; Riou JF; Bailly C
Anticancer Drug Des; 1998 Jul; 13(5):407-15. PubMed ID: 9702207
[TBL] [Abstract][Full Text] [Related]
18. Antitumor potential of aza-bioisosterism in anthracenedione-based drugs.
Sissi C; Palumbo M
Curr Top Med Chem; 2004; 4(2):219-30. PubMed ID: 14754455
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of the low activity of antitumor anthracenediones, mitoxantrone and ametantrone, in oxygen radical generation catalyzed by NADH dehydrogenase. Enzymatic and molecular modelling studies.
Tarasiuk J; Mazerski J; Tkaczyk-Gobis K; Borowski E
Eur J Med Chem; 2005 Apr; 40(4):321-8. PubMed ID: 15804531
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
